Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

ANALYST COVERAGE

wolfe-research-initiates-coverage-of-neurocrine-biosciences-(nbix)-with-outperform-recommendation

Wolfe Research Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform Recommendation

Feb 24, 2026

Fintel reports that on February 24, 2026, Wolfe Research initiated coverage of Neurocrine Biosciences (NasdaqGS:NBIX) with a Outperform…

Read more
igc-pharma-notes-updated-research-coverage-from-ascendiant-capital-markets

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

Feb 24, 2026

Press Release • Feb 24, 2026 08:30 EST POTOMAC, Md., February 24, 2026 (Newswire.com) – IGC Pharma, Inc.…

Read more
wolfe-research-initiates-xenon-pharmaceuticals-stock-coverage-with-outperform-rating

Wolfe Research initiates Xenon Pharmaceuticals stock coverage with outperform rating

Feb 24, 2026

Wolfe Research initiates Xenon Pharmaceuticals stock coverage with outperform rating

Read more
couloir-capital-is-pleased-to-announce-that-it-has-updated-its-research-coverage-on-endurance-gold

Couloir Capital is Pleased to Announce That it Has Updated its Research Coverage on Endurance Gold

Feb 24, 2026

Couloir Capital is pleased to announce that it has updated its research coverage on Endurance Gold Corporation (TSXV:…

Read more
couloir-capital-is-pleased-to-announce-that-it-has-updated-its-research-coverage-on-almonty-industries

Couloir Capital is Pleased to Announce That it Has Updated its Research Coverage on Almonty Industries

Feb 24, 2026

Vancouver, British Columbia–(Newsfile Corp. – February 24, 2026) – Couloir Capital is pleased to announce that it has…

Read more
analyst-lifts-igc-pharma-price-target-to-$5-in-new-research-note

Analyst lifts IGC Pharma price target to $5 in new research note

Feb 24, 2026

IGC Pharma (NYSE American: IGC) announced that Ascendiant Capital Markets issued updated equity research coverage and raised its…

Read more
acadia-pharmaceuticals-(acad)-receives-new-analyst-coverage-with-‘outperform’-rating

ACADIA Pharmaceuticals (ACAD) Receives New Analyst Coverage with ‘Outperform’ Rating

Feb 24, 2026

Key Takeaways Wolfe Research initiates coverage on ACADIA Pharmaceuticals with an ‘Outperform’ rating and a price target of…

Read more
morgan-stanley-maintains-overweight-on-issdy-(iss-a/s),-pt-dkk-258-feb-2026

Morgan Stanley Maintains Overweight on ISSDY (ISS A/S), PT DKK 258 Feb 2026

Feb 24, 2026

On February 23, 2026, Morgan Stanley maintained Overweight on ISS A/S (ISSDY) and raised its price target to…

Read more
morgan-stanley-maintains-underweight-on-saabf-saab-ab-(publ)-feb-23-2026

Morgan Stanley maintains Underweight on SAABF Saab AB (publ) Feb 23 2026

Feb 24, 2026

Morgan Stanley maintained Underweight on SAABF on February 23, 2026, while raising the price target to SEK 540…

Read more
deutsche-bank-maintains-buy-on-orany-(orange-sa)-feb-23,-2026,-pt-e18.50

Deutsche Bank Maintains Buy on ORANY (Orange S.A.) Feb 23, 2026, PT €18.50

Feb 24, 2026

Deutsche Bank on Feb 23, 2026 maintained Buy on ORANY and raised its price target to €18.50 from…

Read more
deutsche-bank-maintains-hold-on-unjcf-unicaja-banco,-sa.-feb-2026

Deutsche Bank Maintains Hold on UNJCF Unicaja Banco, S.A. Feb 2026

Feb 24, 2026

UNJCF analyst rating: Deutsche Bank on February 23, 2026 maintained a Hold on Unicaja Banco, S.A. and raised…

Read more
goldman-sachs,-hc-wainwright-maintain-buy-on-immunitybio,-inc.-(ibrx)-feb-2026

Goldman Sachs, H.C. Wainwright Maintain Buy on ImmunityBio, Inc. (IBRX) Feb 2026

Feb 24, 2026

IBRX analyst rating: Goldman Sachs and H.C. Wainwright maintained Buy on ImmunityBio, Inc. (IBRX) on February 23, 2026.…

Read more
  1. Pages:
  2. «
  3. 1
  4. 2
  5. 3
  6. 4
  7. 5
  8. 6
  9. 7
  10. ...
  11. 350
  12. »

Posts pagination

Newer posts Page 1 … Page 3 … Page 350 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.